1. Home
  2. NKTR vs CBAN Comparison

NKTR vs CBAN Comparison

Compare NKTR & CBAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKTR
  • CBAN
  • Stock Information
  • Founded
  • NKTR 1990
  • CBAN 1975
  • Country
  • NKTR United States
  • CBAN United States
  • Employees
  • NKTR N/A
  • CBAN N/A
  • Industry
  • NKTR Biotechnology: Pharmaceutical Preparations
  • CBAN Major Banks
  • Sector
  • NKTR Health Care
  • CBAN Finance
  • Exchange
  • NKTR Nasdaq
  • CBAN Nasdaq
  • Market Cap
  • NKTR 247.9M
  • CBAN 285.3M
  • IPO Year
  • NKTR 1994
  • CBAN 1998
  • Fundamental
  • Price
  • NKTR $0.90
  • CBAN $16.00
  • Analyst Decision
  • NKTR Strong Buy
  • CBAN
  • Analyst Count
  • NKTR 5
  • CBAN 0
  • Target Price
  • NKTR $4.50
  • CBAN N/A
  • AVG Volume (30 Days)
  • NKTR 1.5M
  • CBAN 45.4K
  • Earning Date
  • NKTR 03-03-2025
  • CBAN 01-22-2025
  • Dividend Yield
  • NKTR N/A
  • CBAN 2.82%
  • EPS Growth
  • NKTR N/A
  • CBAN 1.70
  • EPS
  • NKTR N/A
  • CBAN 1.25
  • Revenue
  • NKTR $93,137,000.00
  • CBAN $108,949,000.00
  • Revenue This Year
  • NKTR $12.85
  • CBAN N/A
  • Revenue Next Year
  • NKTR N/A
  • CBAN $6.05
  • P/E Ratio
  • NKTR N/A
  • CBAN $12.77
  • Revenue Growth
  • NKTR 5.53
  • CBAN N/A
  • 52 Week Low
  • NKTR $0.50
  • CBAN $10.33
  • 52 Week High
  • NKTR $1.93
  • CBAN $18.49
  • Technical
  • Relative Strength Index (RSI)
  • NKTR 40.16
  • CBAN 50.02
  • Support Level
  • NKTR $0.87
  • CBAN $16.09
  • Resistance Level
  • NKTR $0.94
  • CBAN $16.18
  • Average True Range (ATR)
  • NKTR 0.09
  • CBAN 0.39
  • MACD
  • NKTR -0.01
  • CBAN 0.06
  • Stochastic Oscillator
  • NKTR 15.63
  • CBAN 75.54

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

About CBAN Colony Bankcorp Inc.

Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division, and small business specialty lending divisions. It generates maximum revenue from the Banking Division.

Share on Social Networks: